Whilst a combination of detailed clinical and neuroimaging assessments together with normal core CSF AD biomarkers values (e.g., Aβ42/40, p-tau, and t-tau) is indicative of a non-AD type dementia, making an accurate clinical diagnosis of secondary tauopathies during life remaining a major challenge. The gene discussed is MAPT; the disease is tauopathy.